Preventing early-onset group B Streptococcal infection in newborn babies
description
Transcript of Preventing early-onset group B Streptococcal infection in newborn babies
Preventing early-onset group B Streptococcal infection
in newborn babies
January 2009 Charity No. 1112065 Company Reg No 5587535
Charity No. 1112065 Company Reg No 5587535 2
Group B Streptococcus – overview 1
Streptococcus agalactiae Group B Strep, Strep B, beta haemolytic Strep
First recognised as a major perinatal pathogen in the 1970s
Incidence of GBS infection increasing in the UK
0 500 1000 1500
2002
2003
2004
2005
2006
2007
Culture proven cases of GBS infection (all ages) in England, Wales & NI
Source: Health Protection Agency
Charity No. 1112065 Company Reg No 5587535 3
Group B Streptococcus – overview 2
Commonest cause of bacterial infection in newborn babies
Underlying rate estimated at 1:1000 newborn babies in the UK UK research suggests actual rate 3.5 per 1000 (Luck et al, 2003)
Mortality rate approximately 11% 50% of survivors of GBS meningitis will have neurological sequelae
Early-onset and late-onset presentation of GBS infection
Up to 90% GBS infection apparent within 48 hours of birth
Remains uniformly sensitive to penicillin Some tolerance to other antibiotics
Clindamycin around 8% is resistant Erythromycin around 11% is resistant
Charity No. 1112065 Company Reg No 5587535 4
Reported cases of GBS bacteraemia in infants*, England & Wales 2000-2007
Source: Health Protection Agency, 2008 *excludes a small number of infants with imprecise age data
0
50
100
150
200
250
300
350
400
450
2000 2001 2002 2003 2004 2005 2006 2007
6-11 months
3-5 months
1-2 months
1-3 weeks
<1week
Charity No. 1112065 Company Reg No 5587535 5
GBS – Colonisation
Normal flora in intestinal tract and vagina Carriage can be intermittent Carriage is asymptomatic Up to 30% adults carry GBS in intestines Up to 25% of women carry GBS in the vagina Occasionally in the throat (around 5%)
90% of adults do not have protective antibodies to GBS
GBS can cross intact amniotic membranes GBS grows well in amniotic fluid
GBS survives well on skin of newborn infants
GBS colonisation at delivery – risk factor for early-onset GBS disease Cultures late in pregnancy can predict GBS colonisation status at delivery
Charity No. 1112065 Company Reg No 5587535 6
Testing Antenatally for GBS carriage
Between 35 and 37 weeks
GBS carriage can be intermittent so best to swab close to delivery.
Sensitive tests taken within 5 weeks of delivery are highly predictive of carriage at delivery (Yancey et al 1996)
Must take vaginal and rectal swabs
Low vaginal plus anorectal swabs (can use either one or two swabs) are much more effective than high vaginal swabs
Must use selective enrichment medium to
culture swabs
LIM broth (10mL Todd-Hewitt broth supplemented with 10µg/mL colistin and 15µg/mL nalidixic acid) then subcultured to blood agar)
Recognised as optimal for detecting GBS carriage by the Royal College of Obstetricians & Gynaecologists and The Health Protection Agency (BSOP 58)
Available privately and from a handful of NHS hospitals (contact GBSS for availability)
STANDARD CULTURE METHOD TOO INSENSITIVE
FOR testing
Standard culture method (direct plating) instead of using enriched culture medium reduces detection by 50%
Charity No. 1112065 Company Reg No 5587535 7
Options to reduce GBS infection in newborn babies
Waiting & treating babies after delivery Too late for some & won’t prevent most GBS infection Difficult to justify
Intravenous antibiotics in labour (IAL) Only effective method of prevention available at present Largest study performed in Chicago (Boyer et al. N Eng J Med
1986;314:1665) Penicillin G recommended (Clindamycin for penicillin-allergic women)
Oral antibiotics Don’t eradicate colonisation or reduce infection Likely to increase resistance Exception is GBS cultured from urine (treat with oral antibiotics and offer
IAL)
Intramuscular antibiotics Theory – reduces GBS presence ≤6 weeks, so given at 35+ weeks One small study – poorly designed & no GBS grown in control or active
group
Charity No. 1112065 Company Reg No 5587535 8
Who should be offered intravenous antibiotics in labour (IAL)?
women who have one or more risk factors (including incidental finding of GBS carriage or GBS +ve urine culture) during the current pregnancy OR
women identified as GBS carriers through testing (using enriched culture media) at 35-37 weeks of pregnancy OR
women identified as GBS carriers through enriched culture media testing at 35-37 weeks of pregnancy and who have one or more other risk factors OR
women found to carry GBS through enriched culture media testing at 35-37 weeks of pregnancy PLUS women who have one or more other risk factors
Women should be offered an informed choice
Charity No. 1112065 Company Reg No 5587535 9
Option 1: Risk Factor ApproachIAL offered to all women with one or more risk factors
Offer intravenous antibiotics in labour (IAL) to women who have:
a previous baby with GBS infection
GBS bacteria found in the urine during the current pregnancy (which should be treated at the time of diagnosis)
GBS found on a vaginal or rectal swab during the current pregnancy
a raised temperature (≥37.8°C) during labour
preterm labour or membrane rupture (<37 completed weeks of pregnancy)
prolonged rupture of membranes (≥18 hours before delivery)
>40% of cases will still occur, since this will only prevent GBS infections where risk factors are apparent in time for IAL to be offered
Supported by RCOG Green Top Guideline No 36
Not tested in a trial
Relatively cheap to introduce & operate (no bacteriological testing costs involved)
Relatively large amounts of antibiotics prescribed (about 30% of all women)
Pros and Cons
Charity No. 1112065 Company Reg No 5587535 10
Up to 80% potential cases prevented A few women will acquire carriage
between testing and delivery*; some carriers will miss or decline testing and some will deliver before test result available
Not tested in a trial ECM testing for GBS carriage not
routinely or widely available in the NHS (despite being recognised as optimal by RCOG & HPA)
More expensive to introduce Relatively large amounts of antibiotics
prescribed (~30% of women)
Option 2: Testing ApproachIAL offered only to women identified as GBS carriers
Offer sensitive enriched culture medium (ECM) testing to all women at 35-37 weeks of pregnancy
Offer intravenous antibiotics in labour (IAL) to women identified as GBS carriers during their current pregnancy
Pros and Cons
* Yancey research found 4% of women with negative results at 35-37 weeks of pregnancy would become positive and 13% of women with positive results would become negative
Charity No. 1112065 Company Reg No 5587535 11
Option 3: Combined Approach 1IAL offered to GBS carriers with a risk factor
Offer all women sensitive enriched culture medium (ECM) testing at 35-37 weeks
Offer intravenous antibiotics in labour (IAL) to those identified as GBS carriers during the current pregnancy who also have one or more risk factors:
Preterm labour or membrane rupture (<37 completed weeks of pregnancy)
Prolonged rupture of membranes (≥18 hours before delivery)
Maternal pyrexia (≥ 37.8oC)
GBS from a urine culture during the current pregnancy
Previous baby with GBS infection
>40% of cases will still occur – this can only prevent GBS infection where risk factors are apparent in time for IAL to be offered
A few women will acquire carriage between testing and delivery (see
previous slide), some carriers will miss or decline testing and some will deliver before test result is available
Well researched
ECM testing for GBS carriage not routinely or widely available in the NHS (despite being recognised as optimal by RCOG & HPA)
More expensive to introduce
Fewer women receive antibiotics ~5%
Pros and Cons
Charity No. 1112065 Company Reg No 5587535 12
Option 4: Combined Approach 2IAL to GBS carriers & to women with 1+ risk factors
Offer all women sensitive enriched culture medium (ECM) testing at 35-37 weeks
Offer intravenous antibiotics in labour (IAL) to those identified as GBS carriers during the current pregnancy plus to any with one or more risk factors:
Preterm labour or membrane rupture (<37 completed weeks)
Prolonged rupture of membranes (≥18 hours before delivery)
Maternal pyrexia (≥ 37.8oC)
GBS from a urine culture during the current pregnancy
Previous baby with GBS infection
Most >80% potential cases prevented
Not tested in a trial
ECM testing for GBS carriage not routinely or widely available in the NHS (despite being recognised as optimal by RCOG & HPA)
Less expensive – fewer women offered sensitive testing as higher-risk women offered IAL without testing
Relatively large amounts of antibiotics prescribed (~30% of pregnant women)
Pros and Cons
Charity No. 1112065 Company Reg No 5587535 13
Incidence of EO and LO GBS in 3 active surveillance areas in USA
00.20.40.60.81
1.21.41.61.82
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
early-onset
late-onset
Source: N Engl J Med 2000;342:15-20 & p.c. A Schuchat
Charity No. 1112065 Company Reg No 5587535 14
UK Guidelines for Prevention: NICE Antenatal Care Guideline CG6 Oct 03 - 1
Don’t recommend screening as “evidence of its clinical effectiveness and cost effectiveness remains uncertain.”
All the evidence shows testing and offering intravenous antibiotics in labour (IAL) to higher-risk women is clinically effective. Where introduced, reductions of over 70% in incidence, including the US, Australia, New Zealand, Belgium, France, Spain & Italy.
The cost/benefit analysis sponsored by the HTA, published September 2007 shows current practice is not cost effective – testing low-risk women and offering IAL to high risk women was shown to be most cost effective while limiting antibiotic use (Preventative strategies for group B streptococcal and other bacterial infections in early infancy: cost effectiveness and value of information analyses. BMJ. 2007 Sep. Colbourn et al)
Guideline updated March 2008 - No update to GBS sections despite significant new evidence since 2003 and despite requests by a number of stakeholders. Next review due March 2010
Charity No. 1112065 Company Reg No 5587535 15
UK Guidelines for Prevention:NICE Antenatal Care Guideline CG6 Oct 03 - 2
“Pregnant women should be offered information based on the current available evidence together with support to enable them to make informed decisions about their care..” Yet information on GBS is not widely nor routinely available.
Sensitive tests for GBS are only available privately and from a handful of NHS hospitals.
Women are not told about the availability of sensitive tests for detecting GBS late in pregnancy.
How can women make an informed decision when they’re not being given the information?
Guideline updated March 2008 - No update to GBS sections despite significant new evidence since 2003 and despite requests by a number of stakeholders. Next review due March 2010
Charity No. 1112065 Company Reg No 5587535 16
UK Guidelines for Prevention: Royal College of Obstetricians & Gynaecologists 1
Risk factor approach Estimates relative risk for morbidity or mortality for
recognised risk factors Incidence assumptions significantly underestimate GBS
infection, so underestimate the relative risks and overestimate the numbers needed to treat for benefit
Authors of the source of incidence figures (Heath et all, 2004) estimate under-reporting of 21-42%
Incidence figures exclude probable cases of GBS infection (Luck et al 2002), including only cases where GBS was culture-proven from a normally sterile site, eg CSF or blood
Incidence of GBS infection in babies increasing (HPA)
RCOG Green Top Guideline No 36 "Prevention of early onset neonatal Group B streptococcal disease" 2003 (currently being reviewed - due 2010)
Charity No. 1112065 Company Reg No 5587535 17
UK Guidelines for Prevention:Royal College of Obstetricians & Gynaecologists 2
Will prevent most lethal cases of EOGBS infection when fully implemented RCOG audit Jan 2007 shows few hospitals fully comply
Until sensitive testing is routinely available for all pregnant women, GBSS endorses these guidelines They are a key starting position to preventing early onset GBS
infection More infections in babies could be prevented by offering sensitive
testing to pregnant women
RCOG Green Top Guideline No 36 "Prevention of early onset neonatal Group B streptococcal disease" 2003 (currently being reviewed - due 2010)
Charity No. 1112065 Company Reg No 5587535 18
GBSS Recommendation: 1
identified as GBS carriers in the current pregnancy with ≥ 1 other risk factors (no testing required)
previous baby with GBS infection positive urine sample during this pregnancy preterm labour or rupture of membranes <37 completed weeks of pregnancy prolonged rupture of membranes ≥18 hours before delivery maternal pyrexia ≥ 37.8oC
Sensitive (enriched culture medium) tests for GBS carriage using rectal & vaginal swabs should be freely
available to all low-risk women at 35-37 weeks of pregnancy
Pregnant women should be informed about GBS, including about testing, as a routine part of their antenatal
care
Intravenous antibiotics in labour should be offered to women:
Charity No. 1112065 Company Reg No 5587535 19
GBSS Recommendation: 2
Pregnant women should be informed about GBS as a routine part of their antenatal care
Where sensitive GBS tests are unavailable in the NHS, pregnant women should be informed how to obtain them privately
Intravenous antibiotics in labour should be offered to women: who have previously had a GBS baby where GBS is found in the urine during the current pregnancy (also
treated at diagnosis) identified as carriers (any test method) during the pregnancy not tested using sensitive tests but with ≥ 1 other risk factors:
Prolonged rupture of membranes ≥18 hours before delivery Preterm labour or membrane rupture <37 completed weeks of pregnancy Maternal pyrexia ≥ 37.8oC
Until sensitive tests for GBS carriage are freely and routinely available to all women at 35-37 weeks of pregnancy:
Charity No. 1112065 Company Reg No 5587535 20
Intrapartum Antimicrobial Prophylaxis
Penicillin G
3 g (or 5 mU) IV initially and then 1.5 g (or 2.5 mU) at 4-hourly intervals until delivery.
Clindamycin
For women who are allergic to penicillin, 900 mg IV every 8 hours until delivery.
Intravenous antibiotics should be given for at least
4 hours before delivery, where possible lesser times are better than nothing and 2+
hours should give considerable reassurance.
Charity No. 1112065 Company Reg No 5587535 21
Option 6: Intravenous Antibiotics in Labour Chart
OfferIntravenous antibiotics at the start of, and at
intervals during, labour to women at raised risk of their baby developing GBS infection
Strongly recommend Intravenous antibiotics at the onset of, and
during, labour to women at particularly high risk of their baby developing GBS infection
One of: Women found to carry GBS during
pregnancy
GBS found in urine during pregnancy
Preterm labour or membrane rupture <37 weeks of pregnancy
Prolonged rupture of membranes ≥ 18-24 hours before delivery
Maternal pyrexia 37.8°C or higher during labour*
Two or more of above risk factors
Previous baby developed GBS infection
*In the presence of an epidural, a slightly raised temperature may be of less significance than in a woman without
Charity No. 1112065 Company Reg No 5587535 22
Paediatric prevention strategy for babies born at higher risk
Signs of possible infection in neonate or mother
Gestational age ≤ 35 weeks of pregnancy
Maternal intravenous antibiotics pre-delivery < 4 hours
Maternal intravenous antibiotics Pre-delivery > 4 hours AND mother with no signs of infection
YES
YES
YES
YES
NO
NO
NO
Full work up
Intravenous antibiotics
Review at 48 hours
Full work up
Intravenous antibiotics
Review at 48 hours
Full work up
Intravenous antibiotics
Review at 48 hours
No work upBaby dischargedParental awareness of early signs of infectionHandout
BABY WORK UP
FBC (Full Blood Count)
CRP (C reactive protein) x2, 12 – 24 hours apart
Blood Culture
2 swabs – throat and periumbilical
Urine antigen Optional, according to availability and personal preference
Charity No. 1112065 Company Reg No 5587535 23
Babies Colonised with GBS
Culture results are ‘history’
Swabs from baby Vaginal swab at time of delivery
Antibiotic treatment for a healthy colonised baby is not indicated
Can send baby home, but ‘educate’ parents
what symptoms to watch for what to do if they develop
Charity No. 1112065 Company Reg No 5587535 24
Transmission of GBS to baby
0.6%Ear ly-o nset G B S in fectio n
(septicaem ia, pneum o n ia and /o r m en ingit is)
99.4%A sym pto m atic
50%B aby co lo n ised w ith G B S
50%N ew bo r n baby no t co lo n ised
M o ther co lo n ised w ith G B S at deliver y(up to 30% o f w o m en)
Mother colonised with GBS at delivery
(up to 30% of women)
50%Baby colonised with GBS
50%Newborn baby not colonised
0.6%Early-onset GBS infection septicaemia, pneumonia and/or
meningitis
99.4%Asymptomatic
Charity No. 1112065 Company Reg No 5587535 25
Types of GBS infection (1)
Apparent within first 6 days of life, and usually within 12 -24 hours of delivery
Usually septicaemia with pneumonia
Typical symptoms
Grunting Poor feeding Lethargy Low blood pressure Irritability Low blood sugar
Even with the best medical care, 10% of babies with EOGBS die
Early-onset GBS infection (EOGBS)
Abnormally high or low temperature Abnormally high or low heart rates Abnormally high or low breathing rates
Charity No. 1112065 Company Reg No 5587535 26
Types of GBS infection (2)
Develops 6 days - 3 months
Usually meningitis with septicaemia
Typical symptoms of late-onset GBS infection
Fever Poor feeding and/or vomiting Impaired consciousness Plus any symptoms of meningitis
Even with the best medical care
5% of babies sick with LOGBS die up to 50% of survivors of GBS meningitis suffer long term handicaps
Late-onset GBS infection (LOGBS)
Charity No. 1112065 Company Reg No 5587535 27
Baby successfully treated for GBS infection
GBS infections have a relatively high incidence of
recurrence (1-3%)
Consider low dose oral penicillin daily for 3
months
Charity No. 1112065 Company Reg No 5587535 28
The Future
Rapid Near Patient Testing
Better than testing at 35-37 weeks in informing which women are carrying GBS in labour
Unfortunately, no tests currently both fast and accurate enough More costly than enriched culture medium testing
Vaccine
Best approach for preventing both EOGBS and LOGBS infection, plus maternal GBS infection and other adult GBS infection
Target would be pregnant women or women before they become pregnant
Vaccine needs to be multivalent Research is urgently needed into developing a viable vaccine for
group B Strep infection Decades away – big concerns re medico-legal issues
Charity No. 1112065 Company Reg No 5587535 29
Key References
Centers for Disease Control & Prevention. Prevention of Perinatal Group B Streptococcal Disease: Revised Guidelines from CDC. MMWR Reports & Recommendations Vol. 51(No. RR 11) 16 August 2002.
Heath PT, Balfour G, Weisner AM, Efstratiou A, Lamagni TL, Tighe H, O'Connell LAF, Cafferkey M, Verlander NQ, Nicoll A & McCartney AC on behalf of the PHLS GBS Working Group. Group B streptococcal disease in UK and Irish Infants <90 days of age. Lancet 2004 Jan 24, Vol 363(9405):292.
Luck S, Torny M, d'Agapeyeff K, Pitt A, Heath P, Breathnach A & Bedford Russell A. Estimated early-onset group B streptococcal neonatal disease. Lancet, 2003 Jun 07; 361(9373): 1953-1954
PHLS Communicable Disease Surveillance Unit. Incidence of group B streptococcal disease in infants aged less than 90 days. CDR weekly Vol. 12(No 16):3. 18 April 2002.
Colbourn TE, Asseburg C, Bojke L, Philips Z, Welton NJ, Claxton K, Ades AE, and Gilbert RE. Preventive strategies for group B streptococcal and other bacterial infections in early infancy: cost effectiveness and value of information analyses. BMJ 2007 335: 655
Royal College of Obstetricians & Gynaecologists Clinical Green Top Guideline. Prevention of Early Onset Neonatal Group B Streptococcal Disease (36) – Nov 2003
Law MR, Palomaki G, Alfirevic Z, Gilbert G, Heath P, McCartney C, Reid T, Schrag S on behalf of the Medical Screening Society Working Group on GBS disease. The prevention of neonatal group B streptococcal disease. J Med Screen 2005;12:60-68.
Yancey MK, Schuchat A, Brown LK, Ventura VL, Markenson GR. The accuracy of late antenatal screening cultures in predicting genital GBS colonization at delivery. Obstet Gynecol Nov 1996; 88(5):811-5.
Charity No. 1112065 Company Reg No 5587535 30
Group B Strep Support
Registered charity set up in 1996
Aims:
Funded by donations
To inform health professionals and individuals how most EOGBS infection can be prevented; and
To offer information and support to families affected by GBS;
To generate continued support for research
into preventing GBS infections.
Charity No. 1112065 Company Reg No 5587535 31
GBSS Materials Available
LEAFLETS GBS & pregnancy (introduction for pregnant
women)
Congratulations on the safe arrival of your baby (introduction for parents of a healthy baby)
Understanding your baby’s GBS infection (introduction for parents of a GBS baby)
For women who carry GBS (detailed leaflet for women who know they carry GBS)
If your baby was infected by GBS (detailed leaflet for parents of babies affected by GBS)
GBS: The Facts (detailed leaflet, including medical reference list)
POSTERS Pregnant? (for pregnant women)
Labour & Delivery Prevention Guidelines Understanding your baby’s GBS
infection – for SCBUs
Saving Babies’ Lives – A2
STICKERS GBS Alert - 35 per page for pregnant women’s notes
I am GBS Aware - 35 per page for pregnant women’s notes
Charity No. 1112065 Company Reg No 5587535 32
GBSS Medical Advisory Panel
Professor Philip Steer, BSc, MD, FRCOG (Chair)
Emeritus professor at Imperial College and consultant obstetrician at the Chelsea and Westminster Hospital in London
Dr Alison Bedford-Russell MRCP
Consultant Neonatologist, Birmingham Heartlands Hospital
Dr A Christine McCartney OBE FRCPath
Director, Regional Microbiology Network, Health Protection Agency Central Office
Charity No. 1112065 Company Reg No 5587535 33
What it’s all about ….
……. healthy babies